Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities

Main|Search|PHGKB




Last Posted: Oct 14, 2018

---

• Hidden 'risk' in polygenic scores: clinical use today could exacerbate health disparities
  AR Martin et al, BIORXIV, October 210, 018
• Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
  de Vries Jeroen K et al. Diabetes, obesity & metabolism 2018 Oct 20 Suppl 324-29
• [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
  Moretta Jessica et al. Bulletin du cancer 2018 Sep
• Examining How Race, Ethnicity, and Ancestry Data Are Used in Biomedical Research
  VL Bonham ret al, JAMA, September 24, 2018
• Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
  Kinney Anita Y et al. Contemporary clinical trials 2018 Sep 73123-135
• Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
  Hurtado-de-Mendoza Alejandra et al. Healthcare (Basel, Switzerland) 2018 Sep 6(3)
• Race, Ancestry, and Reporting in Medical Journals
  RS Cooper et al, JAMA September 24, 2018
• Should Electronic Health Record-Derived Social and Behavioral Data Be Used in Precision Medicine Research?
  Hollister Brittany et al. AMA journal of ethics 2018 Sep 20(9) E873-880
• What Precision Medicine Can Learn from Rare Genetic Disease Research and Translation.
  Tabor Holly K et al. AMA journal of ethics 2018 Sep 20(9) E834-840
• Global Inequities in Precision Medicine and Molecular Cancer Research.
  Drake Thomas M et al. Frontiers in oncology 2018 8346

more